Salarius Pharmaceuticals (SLRX) Short Interest Ratio & Short Volume $5.77 +0.45 (+8.46%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$5.63 -0.14 (-2.44%) As of 08/22/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock Salarius Pharmaceuticals Short Interest DataSalarius Pharmaceuticals (SLRX) has a short interest of 803,600 shares, representing 10.59% of the float (the number of shares available for trading by the public). This marks a 18.44% increase in short interest from the previous month. The short interest ratio (days to cover) is 0.3, indicating that it would take 0.3 days of the average trading volume of 432,246 shares to cover all short positions.Current Short Interest803,600 sharesPrevious Short Interest678,500 sharesChange Vs. Previous Month+18.44%Dollar Volume Sold Short$481.60 thousandShort Interest Ratio0.3 Days to CoverLast Record DateJuly 31, 2025Outstanding Shares510,000 sharesFloat Size7,590,000 sharesShort Percent of Float10.59%Today's Trading Volume36,047 sharesAverage Trading Volume432,246 sharesToday's Volume Vs. Average8% Short Selling Salarius Pharmaceuticals? Sign up to receive the latest short interest report for Salarius Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartSLRX Short Interest Over TimeSLRX Days to Cover Over TimeSLRX Percentage of Float Shorted Over Time Salarius Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/31/2025803,600 shares $481.60 thousand +18.4%10.6%0.3 $0.60 7/15/2025678,500 shares $460.70 thousand -3.9%32.2%0.6 $0.68 6/30/2025705,800 shares $632.33 thousand +2,147.8%33.5%0.6 $0.90 6/15/202531,400 shares $20.64 thousand -34.6%1.5%0 $0.66 5/31/202548,000 shares $37.44 thousand -8.9%2.3%0.2 $0.78 5/15/202552,700 shares $44.78 thousand -37.4%2.5%0.2 $0.85 4/30/202584,200 shares $59.78 thousand -25.4%4.1%0.3 $0.71 4/15/2025112,900 shares $81.29 thousand -18.3%5.4%0.4 $0.72 3/31/2025138,200 shares $104.20 thousand +242.1%8.1%0.1 $0.75 3/15/202540,400 shares $39.19 thousand -52.9%2.4%0 $0.97 Get the Latest News and Ratings for SLRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Salarius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 2/28/202585,700 shares $92.56 thousand +724.0%5.5%0 $1.08 2/15/202510,400 shares $16.85 thousand -46.1%0.7%0 $1.62 1/31/202519,300 shares $43.23 thousand -93.8%1.3%0 $2.24 1/15/2025311,700 shares $785.48 thousand +902.3%20.2%0.2 $2.52 12/31/202431,100 shares $57.22 thousand +18.3%2.2%0.1 $1.84 12/15/202426,300 shares $38.66 thousand -27.8%1.9%0.1 $1.47 11/30/202436,400 shares $52.05 thousand -33.8%2.6%0.1 $1.43 11/15/202455,000 shares $73.70 thousand -15.4%3.9%0.2 $1.34 10/31/202465,000 shares $104.65 thousand +4,233.3%4.6%0.2 $1.61 10/15/20241,500 shares $2.28 thousand -90.0%0.1%0 $1.52 9/30/202415,000 shares $21.60 thousand +59.6%1.1%0 $1.44 9/15/20249,400 shares $14.66 thousand -38.6%0.7%0 $1.56 8/31/202415,300 shares $25.40 thousand -64.0%1.1%0 $1.66 8/15/202442,500 shares $85.43 thousand -50.8%3.2%0 $2.01 7/31/202486,300 shares $220.93 thousand +44.1%15.4%0 $2.56 7/15/202459,900 shares $106.62 thousand +215.3%10.7%0 $1.78 6/30/202419,000 shares $45.22 thousand +375.0%27.1%0.9 $2.38 6/15/20244,000 shares $13.53 thousand -85.4%5.7%0.2 $3.38 5/31/202427,300 shares $12.65 thousand -18.5%0.6%0.2 $0.46 5/15/202433,500 shares $15.34 thousand -54.5%0.8%0.3 $0.46 4/30/202473,600 shares $36.73 thousand -36.3%1.7%0.6 $0.50 4/15/2024115,600 shares $57.80 thousand -57.0%2.6%1 $0.50 3/31/2024268,900 shares $142.14 thousand +1,767.4%6.7%2.4 $0.53 3/15/202414,400 shares $9.36 thousand -20.0%0.4%0.1 $0.65 2/29/202418,000 shares $12.06 thousand +227.3%0.5%0.6 $0.67 2/15/20245,500 shares $3.25 thousand -33.7%0.2%0.2 $0.59 1/31/20248,300 shares $4.56 thousand +36.1%0.2%0.2 $0.55 1/15/20246,100 shares $3.72 thousand -37.1%0.2%0.2 $0.61 12/31/20239,700 shares $6.31 thousand +38.6%0.3%0.3 $0.65 12/15/20237,000 shares $4.52 thousand -71.9%0.2%0.1 $0.65Alex’s “Next Magnificent Seven” stocks (Ad)The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Magnificent Seven—seven stocks he believes could deliver similar gains in under six years. His full breakdown is now live.Watch the “Next Magnificent Seven” presentation here 11/30/202324,900 shares $17.68 thousand -56.0%0.7%0.4 $0.71 11/15/202356,600 shares $40.75 thousand -22.7%1.6%1.1 $0.72 10/31/202373,200 shares $61.33 thousand +136.9%2.3%1.2 $0.84 10/15/202330,900 shares $21.32 thousand +62.6%0.9%0.5 $0.69 9/30/202319,000 shares $12.50 thousand -6.4%0.6%0.3 $0.66 9/15/202320,300 shares $17.40 thousand -26.5%0.6%0.4 $0.86 8/31/202327,600 shares $24.29 thousand +162.9%0.8%0.5 $0.88 8/15/202310,500 shares $7.49 thousand +54.4%0.3%0.2 $0.71 7/31/20236,800 shares $6.25 thousand -60.9%0.2%0.1 $0.92 7/15/202317,400 shares $19.31 thousand -44.8%0.6%0.2 $1.11 6/30/202331,500 shares $46.94 thousand -41.2%1.0%0.3 $1.49 6/15/202353,600 shares $85.22 thousand +9.6%1.7%0.5 $1.59 5/31/202348,900 shares $68.95 thousand -48.4%2.1%0.5 $1.41 5/15/202394,700 shares $136.37 thousand -16.1%4.2%1 $1.44 4/30/2023112,800 shares $200.78 thousand -11.9%5.4%1.3 $1.78 4/15/2023128,000 shares $220.16 thousand +6.1%6.1%2.5 $1.72 3/31/2023120,700 shares $230.54 thousand -4.2%5.8%0.8 $1.91 3/15/2023126,000 shares $255.78 thousand -4.0%6.6%0.7 $2.03 2/28/2023131,300 shares $279.67 thousand +16.7%6.8%0.7 $2.13 2/15/2023112,500 shares $252.00 thousand +11.3%5.9%0.6 $2.24 1/31/2023101,100 shares $260.84 thousand +37.7%5.2%0.6 $2.58 1/15/202373,400 shares $194.51 thousand +272.6%3.8%0.4 $2.65 12/30/202219,700 shares $30.14 thousand -46.6%1.0%0.3 $1.53 12/15/202236,900 shares $55.72 thousand +93.2%1.9%0.8 $1.51 11/30/202219,100 shares $36.86 thousand -12.0%1.0%0.4 $1.93 11/15/202221,700 shares $46.66 thousand +100.9%1.1%0.5 $2.15 10/31/202210,800 shares $21.92 thousand -31.2%0.5%0.3 $2.03 10/15/202215,700 shares $71.04 thousand -95.8%0.8%0.4 $4.53 9/30/2022371,000 shares $72.35 thousand -8.4%N/A0.9 $0.20 9/15/2022405,000 shares $95.90 thousand +9.6%N/A0.8 $0.24 8/31/2022369,500 shares $74.27 thousand -16.3%N/A0.7 $0.20 8/15/2022441,600 shares $99.36 thousand +257.3%N/A0.7 $0.23 7/31/2022123,600 shares $23.51 thousand +7.3%N/A0.1 $0.19 7/15/2022115,200 shares $21.88 thousand -33.8%N/A0.1 $0.19 6/30/2022174,100 shares $36.56 thousand -54.6%N/A0.1 $0.21 6/15/2022383,300 shares $77.73 thousand -9.8%N/A0.3 $0.20 5/31/2022425,000 shares $76.63 thousand -3.8%N/A0.4 $0.18 5/15/2022441,800 shares $83.01 thousand -26.6%N/A0.4 $0.19 4/30/2022602,200 shares $121.64 thousand +31.4%N/A1.1 $0.20 4/15/2022458,300 shares $163.66 thousand -14.7%N/A1.1 $0.36 3/31/2022537,100 shares $213.82 thousand +11.7%N/A1.3 $0.40 3/15/2022480,900 shares $165.43 thousand -23.8%N/A1 $0.34 2/28/2022630,900 shares $252.42 thousand +0.4%N/A1.8 $0.40 2/15/2022628,200 shares $285.83 thousand -3.7%N/A1.7 $0.46 1/31/2022652,400 shares $293.58 thousand -2.0%4.5%1.5 $0.45 1/15/2022665,600 shares $312.83 thousand +4.2%4.6%1.4 $0.47 12/31/2021638,500 shares $316.44 thousand -7.3%4.4%1.3 $0.50 12/15/2021688,600 shares $365.85 thousand -35.0%4.7%1.4 $0.53 11/30/20211,060,000 shares $689 thousand +1.0%7.3%1.5 $0.65 11/15/20211,050,000 shares $796.95 thousand +7.5%7.2%1.1 $0.76Alex’s “Next Magnificent Seven” stocks (Ad)The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Magnificent Seven—seven stocks he believes could deliver similar gains in under six years. His full breakdown is now live.Watch the “Next Magnificent Seven” presentation here 10/29/2021976,600 shares $808.33 thousand -0.2%6.7%0.8 $0.83 10/15/2021978,900 shares $886.00 thousand -24.1%6.7%0.8 $0.91 9/30/20211,290,000 shares $1.32 million -4.4%8.9%1 $1.02 9/15/20211,350,000 shares $1.39 million -2.9%9.3%1 $1.03 8/31/20211,390,000 shares $1.45 million +9.5%9.6%1 $1.04 8/13/20211,270,000 shares $1.17 million -8.0%8.8%0.7 $0.92 7/30/20211,380,000 shares $1.12 million -9.2%9.5%0.8 $0.81 7/15/20211,520,000 shares $1.38 million -19.2%10.5%0.9 $0.91 6/30/20211,880,000 shares $1.99 million +0.5%13.0%1.1 $1.06 6/15/20211,870,000 shares $2.24 million +14.7%12.9%1.1 $1.20 5/28/20211,630,000 shares $2.09 million -2.4%11.3%1 $1.28 5/14/20211,670,000 shares $2.04 million +29.5%N/A1.3 $1.22 4/30/20211,290,000 shares $1.72 million -5.8%N/A0.6 $1.33 4/15/20211,370,000 shares $1.78 million -12.7%N/A0.6 $1.30 3/31/20211,570,000 shares $2.25 million +41.4%N/A0.6 $1.43 3/15/20211,110,000 shares $1.81 million -41.6%N/A0.4 $1.63 2/26/20211,900,000 shares $3.67 million +15.2%N/A0.7 $1.93 2/12/20211,650,000 shares $4.36 million +202.6%N/A0.6 $2.64 1/29/2021545,200 shares $594.27 thousand -11.3%N/A0.3 $1.09 1/15/2021614,300 shares $712.59 thousand +7.3%N/A0.6 $1.16 12/31/2020572,800 shares $510.94 thousand +22.8%N/A0.7 $0.89 12/15/2020466,600 shares $407.30 thousand -2.1%N/A0.8 $0.87 11/30/2020476,400 shares $325.86 thousand -18.6%N/A1.1 $0.68 11/15/2020585,000 shares $427.05 thousand +3.0%N/A3.9 $0.73 10/30/2020568,000 shares $382.43 thousand -11.4%N/A3.6 $0.67 10/15/2020640,800 shares $583.13 thousand -5.2%N/A2.8 $0.91 9/30/2020675,900 shares $570.39 thousand +22.7%N/A2.9 $0.84 9/15/2020551,100 shares $506.74 thousand -4.2%N/A2.2 $0.92 8/31/2020575,000 shares $540.50 thousand +1.4%N/A1.6 $0.94 SLRX Short Interest - Frequently Asked Questions What is Salarius Pharmaceuticals' current short interest? Short interest is the volume of Salarius Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of July 31st, traders have sold 803,600 shares of SLRX short. 10.59% of Salarius Pharmaceuticals' shares are currently sold short. Learn More on Salarius Pharmaceuticals' current short interest. What is a good short interest percentage for Salarius Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 10.59% of Salarius Pharmaceuticals' floating shares are currently sold short. Is Salarius Pharmaceuticals' short interest increasing or decreasing? Salarius Pharmaceuticals saw a increase in short interest during the month of July. As of July 31st, there was short interest totaling 803,600 shares, an increase of 18.4% from the previous total of 678,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Salarius Pharmaceuticals' float size? Salarius Pharmaceuticals currently has issued a total of 510,000 shares. Some of Salarius Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Salarius Pharmaceuticals currently has a public float of 7,590,000 shares. How does Salarius Pharmaceuticals' short interest compare to its competitors? 10.59% of Salarius Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Salarius Pharmaceuticals: GRI Bio, Inc. (7.13%), Virax Biolabs Group Limited (0.38%), CERo Therapeutics Holdings, Inc. (4.27%), Redhill Biopharma Ltd. (4.68%), Qualigen Therapeutics, Inc. (3.51%), BioVie Inc. (8.15%), PMGC Holdings Inc. (7.84%), Enveric Biosciences, Inc. (11.92%), CNS Pharmaceuticals, Inc. (7.71%), Lipella Pharmaceuticals Inc. (0.10%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.87 billion), Invesco QQQ ($30.12 billion), iShares Russell 2000 ETF ($19.85 billion), iShares 20+ Year Treasury Bond ETF ($10.34 billion), Strategy Inc ($8.98 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.61 billion), SPDR S&P Biotech ETF ($6.81 billion), Invesco S&P 500 Equal Weight ETF ($6.14 billion), Palo Alto Networks, Inc. ($5.97 billion), and Super Micro Computer, Inc. ($5.28 billion). View all of the most shorted stocks. What does it mean to sell short Salarius Pharmaceuticals stock? Short selling SLRX is an investing strategy that aims to generate trading profit from Salarius Pharmaceuticals as its price is falling. SLRX shares are trading up $0.45 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Salarius Pharmaceuticals? A short squeeze for Salarius Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of SLRX, which in turn drives the price of the stock up even further. How often is Salarius Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SLRX, twice per month. The most recent reporting period available is July, 31 2025. More Short Interest Resources from MarketBeat Related Companies GRI Short Interest VRAX Short Interest CERO Short Interest RDHL Short Interest QLGN Short Interest BIVI Short Interest ELAB Short Interest ENVB Short Interest CNSP Short Interest LIPO Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:SLRX) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Salarius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Salarius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access